Related Experiment Videos
A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and
Abstract:
The efficacy, safety and tolerance of imipenem/cilastatin and moxalactam were compared in a randomized trial in the United States involving 19 centers and 441 patients. Significantly more organisms were susceptible to imipenem than moxalactam. Although the bacteriological outcomes were similar, the clinical outcome was significantly better in the imipenem/cilastatin treatment group. The incidence of colonization and superinfection was similar in both groups. Moxalactam was less irritating at the site of injection than imipenem/cilastatin. The safety profiles were similar except for bleeding episodes in the moxalactam group.
Insights
Imipenem/cilastatin demonstrated superior clinical outcomes compared to moxalactam in a randomized trial. While both antibiotics showed similar bacteriological efficacy, imipenem/cilastatin offered better patient results.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Antibiotic resistance is a growing global health concern.
- Imipenem/cilastatin and moxalactam are broad-spectrum antibiotics used to treat various bacterial infections.
- Comparative studies are essential to determine optimal antibiotic selection.
Purpose of the Study:
- To compare the efficacy, safety, and tolerance of imipenem/cilastatin versus moxalactam.
- To evaluate clinical and bacteriological outcomes in patients treated with these antibiotics.
- To assess adverse events and patient tolerance associated with each treatment.
Main Methods:
- A randomized, multi-center trial was conducted in the United States.
- 441 patients were enrolled and randomized to receive either imipenem/cilastatin or moxalactam.
- Efficacy, safety, and tolerance were assessed throughout the treatment period.
Main Results:
- A higher susceptibility rate of organisms to imipenem/cilastatin was observed compared to moxalactam.
- Clinical outcomes were significantly better in the imipenem/cilastatin group.
- Bacteriological outcomes, colonization, and superinfection rates were similar between the groups.
- Moxalactam showed less injection site irritation, but was associated with more bleeding episodes.
Conclusions:
- Imipenem/cilastatin offers superior clinical efficacy compared to moxalactam.
- Both antibiotics have comparable bacteriological outcomes and similar rates of colonization and superinfection.
- While moxalactam is less irritating, potential bleeding episodes warrant consideration in safety profiles.